Home » Benefits of Farxiga in heart failure

Benefits of Farxiga in heart failure

In taking the type 2 diabetes medication Farxiga (dapagliflozin) can give years of life to those suffering from a common type of heart disease, as per an article released in JAMA Cardiology.

Although Farxiga was initially developed in order to help treat diabetes type 2, it is now being studied and then approved to treat other health issues, too. In May of 2020 the drug was approved by the U.S. Food and Drug Administration (FDA) to be used as an option for treating heart failure that has a reduced ejection fraction, irrespective of whether someone is diabetic. Then , in April 2021 Farxiga was approved as a remedy for chronic kidney disease after clinical trials that were cut short because they demonstrated an “overwhelming” benefits for this condition.

The benefits of Farxiga’s Heart failure

Researchers have demonstrated that based on results from the clinical trial of people suffering from heart disease It’s possible that taking Farxiga can add years of life to those who suffer from this condition. the result was derived from the data, rather than demonstrated, as the trial hasn’t lasted for long enough to demonstrate that the medication adds years of living. In this “exploratory study,” researchers looked at the data from a study of 474 patients with heart failure that were randomly assigned orally Farxiga as well as a placebo (inactive pills). Participants were enrolled from February 2017 through August 2018, and were monitored until June of 2019, with an average follow-up time that was 17.6 months.

In the participants who received Farxiga in the course of this study, 10 mg the drug were administered once every day as an additional the standard therapy for patients suffering from heart failure. The primary outcome they wanted to determine was the length of time between the moment that participants required hospitalization or an urgent care appointment that required IV (IV) treatments for heart failure or until they passed away from heart-related causes. Based on the findings of other studies that have revealed about the connection between heart failure hospitalization and death due to causes of cardiovascular or other causes The researchers then utilized the information on Farxiga to calculate how long people could have to live if taking the medication for the remainder of their lives.

The study discovered that a person aged 65 suffering from heart failure is expected to live another 6.2 years without suffering a heart attack if they were to take the placebo, as well as an extra 8.3 years should they used Farxiga. In the case of deaths from any cause and the time to die for a 65-year-old who took an placebo was calculated at 9.1 years. For Farxiga this was 10.8 years. This is more than 1.7 days of existence. Similar results were found when the researchers calculated the results for individuals with different ages.

“These findings suggest that the use of Farxiga can result in significant clinical benefits in extrapolating events-free survival and overall,” the researchers wrote. “These results could be useful in promoting the advantages of this treatment” for patients with heart failure.

Click here for the Farxiga assistance program.